The Biologic Alternative Already Trusted Worldwide: What American Patients Should Understand About Biosimilars

In the treatment of rheumatoid arthritis, Crohn's disease, certain blood cancers, and Type 1 diabetes, biologic medications have transformed clinical outcomes over the past two decades. They have also placed an extraordinary financial burden on patients and healthcare systems alike. A single biologic infusion can cost tens of thousands of dollars annually, making these therapies among the most expensive in modern medicine. What many American patients do not yet fully appreciate is that lower-cost alternatives—biosimilars—have been available in Europe since 2006, are widely used across Asia, and have received FDA approval in the United States. The gap between approval and adoption, however, remains significant, and understanding why requires a clear-eyed look at science, economics, and institutional inertia.

Biologics and Biosimilars: Understanding the Distinction

To appreciate what a biosimilar is, it helps to first understand what distinguishes a biologic from a conventional small-molecule drug. Traditional pharmaceuticals—aspirin, metformin, lisinopril—are chemically synthesized compounds with relatively simple molecular structures. They can be replicated exactly, which is why generic versions of these drugs are chemically identical to the originals.

Biologics are fundamentally different. They are large, complex molecules derived from living cells—typically proteins engineered through biotechnology. Their size and structural complexity mean that no two manufacturing processes will produce molecules that are perfectly identical at the molecular level, even within the same factory. This complexity is precisely why the term "biosimilar" is used rather than "biologic generic." A biosimilar is not an exact copy; it is a highly similar version of an approved biologic, demonstrated through extensive comparative testing to have no clinically meaningful differences in safety, purity, or potency.

The FDA's approval pathway for biosimilars, established under the Biologics Price Competition and Innovation Act of 2009, requires manufacturers to submit robust analytical, preclinical, and clinical data proving that their product performs equivalently to the reference biologic. This is a rigorous standard—considerably more demanding than the pathway for conventional generics.

A Decade of Global Experience the US Has Largely Overlooked

The European Medicines Agency approved its first biosimilar in 2006. In the years since, the European Union has accumulated an extensive real-world safety and efficacy record across dozens of biosimilar products and millions of patient treatment years. Countries including Norway, Denmark, and Germany have achieved biosimilar uptake rates exceeding 80 percent in eligible patient populations, generating billions of euros in healthcare savings that have been redirected toward broader patient access.

In Japan and South Korea, biosimilar adoption has similarly accelerated, driven by government reimbursement policies that actively incentivize prescribing. The global clinical evidence base is, at this point, substantial. Studies published in peer-reviewed journals including the New England Journal of Medicine and The Lancet have consistently found biosimilars to be as safe and effective as their reference biologics across conditions including ankylosing spondylitis, plaque psoriasis, and non-Hodgkin lymphoma.

The United States, despite approving its first biosimilar in 2015, has lagged considerably. As of 2024, the US biosimilar market share in eligible categories remains well below European benchmarks, a discrepancy with real financial consequences for patients.

The Conditions Where Biosimilars Are Relevant

Biosimilars are not a niche category. They are approved and available for some of the most prevalent and costly conditions in American healthcare.

Inflammatory and Autoimmune Conditions: Multiple biosimilars to adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade) are now FDA-approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. These are conditions affecting millions of Americans who may currently be paying list prices for reference biologics when biosimilar options exist at significantly lower cost.

Oncology Supportive Care: Biosimilars to filgrastim (Neupogen), used to prevent infection in chemotherapy patients, and to bevacizumab (Avastin) and trastuzumab (Herceptin), used in the treatment of certain cancers, are approved and available. In oncology, where treatment costs routinely reach six figures annually, the financial stakes are particularly high.

Diabetes Management: Biosimilar insulins, including products referencing insulin glargine (Lantus) and insulin lispro (Humalog), have received FDA approval. For the approximately 8 million Americans who use insulin, these products represent a potentially significant reduction in one of the most discussed drug pricing crises in recent years.

Why Uptake Remains Low: The Barriers Explained

If biosimilars are safe, effective, and less expensive, why are they not more widely used? The answer involves a convergence of financial incentives, institutional hesitancy, and patient psychology.

Physician hesitancy is a documented phenomenon. Surveys of US rheumatologists and oncologists reveal that a meaningful proportion express concerns about switching stable patients from a reference biologic to a biosimilar—concerns that the accumulated international evidence largely does not support for most patient populations. Medical education about biosimilars has historically been limited, and pharmaceutical manufacturer detailing has not always presented biosimilar data in a balanced manner.

Insurance and pharmacy benefit manager (PBM) dynamics further complicate the picture. In some cases, reference biologic manufacturers offer substantial rebates to PBMs in exchange for preferred formulary placement, meaning an insurer's drug list may actually make the more expensive reference product cheaper to the patient than the biosimilar—a perverse outcome that has drawn regulatory scrutiny.

Patient familiarity and inertia also play a role. Patients who have achieved stable disease control on a reference biologic may be understandably reluctant to change, even when clinical evidence supports the safety of doing so.

A Roadmap for American Patients

Navigating this landscape requires proactive engagement. Patients currently taking biologic medications for any of the conditions listed above should consider initiating a direct conversation with their prescribing physician specifically about biosimilar options. Asking whether an FDA-approved biosimilar exists for your current biologic, whether your insurance formulary covers it, and what the comparative out-of-pocket cost would be are all reasonable and clinically appropriate questions.

Patient assistance and manufacturer copay programs exist for several biosimilar products and may further reduce cost differentials. The FDA maintains a publicly accessible Purple Book database listing all approved biological products and their biosimilar counterparts, which patients and caregivers can consult directly.

Advocacy organizations including the Alliance for Safe Biologic Medicines and the Biosimilars Forum publish patient-facing educational materials. Engaging with these resources can help patients approach clinical conversations from a more informed position.

The global track record of biosimilars is now long enough and robust enough that their underutilization in the United States represents a genuine policy and practice gap—one with direct consequences for patient affordability and access. The rest of the world has largely moved forward. American patients deserve the same opportunity.

---

Health Pharmacy Worlds connects patients with global pharmaceutical knowledge to support informed healthcare decisions. This article is intended for educational purposes and should not replace consultation with a licensed healthcare provider.